Skip Main Navigation Links Jump to Footer
ACS NanoVolume 10, Issue 4, 26 April 2016, Pages 3886-3899

Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine(Review)

  • Fais, S.,
  • O'Driscoll, L.,
  • Borras, F.E.,
  • Buzas, E.,
  • Camussi, G.,
  • Cappello, F.,
  • Carvalho, J.,
  • Cordeiro Da Silva, A.,
  • Del Portillo, H.,
  • El Andaloussi, S.,
  • Ficko Trček, T.,
  • Furlan, R.,
  • Hendrix, A.,
  • Gursel, I.,
  • Kralj-Iglic, V.,
  • Kaeffer, B.,
  • Kosanovic, M.,
  • Lekka, M.E.,
  • Lipps, G.,
  • Logozzi, M.,
  • Marcilla, A.,
  • Sammar, M.,
  • Llorente, A.,
  • Nazarenko, I.,
  • Oliveira, C.,
  • Pocsfalvi, G.,
  • Rajendran, L.,
  • Raposo, G.,
  • Rohde, E.,
  • Siljander, P.,
  • Van Niel, G.,
  • Vasconcelos, M.H.,
  • Yáñez-Mó, M.,
  • Yliperttula, M.L.,
  • Zarovni, N.,
  • Zavec, A.B.,
  • Giebel, B.
  • View Correspondence (jump link)
  • aAnti-Tumor Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, 00161, Italy
  • bSchool of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland
  • cIVECAT-Group, Germans Trias i Pujol Research Institute (IGTP), Nephrology Service, Germans Trias i Pujol University Hospital, Campus Can Ruti, Badalona, 08916, Spain
  • dDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, 1085, Hungary
  • eMolecular Biotechnology Center, Department of Medical Sciences, University of Turin, 8 Turin, Italy
  • fHuman Anatomy Section, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Euro-Mediterranean Institute of Science and Technology, Palermo, 90133, Italy
  • gInstituto de Investigação e Inovação em Saúde (i3S), University of Porto (IPATIMUP), Porto, 4200-135, Portugal
  • hInstitute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Porto, 4200-135, Portugal
  • iDepartment of Pathology and Oncology, Faculty of Medicine, University of Porto, Porto, 4200-319, Portugal
  • jDepartment of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, 4050-313, Portugal
  • kInstitute for Molecular and Cell Biology, Rua Campo Alegre, Porto, 4150-180, Portugal
  • lICREA, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, 08036, Spain
  • mICREA, Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, 08916, Spain
  • nDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, 17177, Sweden
  • oDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, OX13QX, United Kingdom
  • pSandoz Biopharmaceuticals-Lek Pharmaceuticals D.d., Mengeš, Slovenia
  • qInstitute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, 20132, Italy
  • rLaboratory of Experimental Cancer Research, Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Gent, 9000, Belgium
  • sScience Faculty, Molecular Biology and Genetics Department, THORLAB- Therapeutic Oligonucleotide Research Lab, Bilkent University, Bilkent, 06800, Turkey
  • tLaboratory of Clinical Biophysics, Faculty of Health Sciences, University of Ljubljana, Ljubljana, 1000, Slovenia
  • uUMR-1280, INRA, University of Nantes, Nantes, 44300, France
  • vDepartment of Immunochemistry and Glycobiology, Institute for the Application of Nuclear Energy, INEP, Univeristy of Belgrade, Belgrade, 11000, Serbia
  • wChemistry Department, University of Ioannina, Ioannina, 45110, Greece
  • xUniversity of Applied Sciences and Arts Northwestern Switzerland, Gründenstrasse 40, Muttenz, 4132, Switzerland
  • yDpto. Biología Celular y Parasitologia, Facultat de Farmacia, Spain
  • zJoint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Health Research Institute la Fe, Universitat de Valencia, València, 46010, Spain
  • aaProf. Ephraim Katzir Department of Biotechnology Engineering, ORT Braude College, Karmiel, 2161002, Israel
  • abDept. of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, 0379, Norway
  • acInstitute for Environmental Health Sciences, Hospital Infection Control, Medical Center, University of Freiburg, Freiburg am Breisgau, 79106, Germany
  • adMass Spectrometry and Proteomics, Institute of Biosciences and BioResources, National Research Council of Italy, Naples, 80131, Italy
  • aeSystems and Cell Biology of Neurodegeneration, University of Zurich, Zurich, 8006, Switzerland
  • afInstitut Curie, PSL Research University, UMR144, Centre de Recherche, Centre National de la Recherche Scientifique, UMR144, 26 rue d'ULM, Paris, 75231, France
  • agSpinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, 5020, Austria
  • ahDepartment of Blood Group Serology and Transfusion Medicine, University Hospital, Salzburger Landeskliniken GesmbH (SALK), Salzburg, 5020, Austria
  • aiDivision of Biochemistry and Biotechnology, Department of Biosciences, India
  • ajDivision of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, 00100, Finland
  • akUnidad de Investigación, Hospital Sta Cristina, IIS-IP, Departamento Biología Molecular, CBM-SO, UAM, Madrid, 28009, Spain
  • alExosomics Siena SpA, Siena, 53100, Italy
  • amLaboratory for Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, 1000, Slovenia
  • anInstitute for Transfusion Medicine, University Hospital Essen, University Duisburg-Essen, Essen, 45147, Germany

Abstract

Recent research has demonstrated that all body fluids assessed contain substantial amounts of vesicles that range in size from 30 to 1000 nm and that are surrounded by phospholipid membranes containing different membrane microdomains such as lipid rafts and caveolae. The most prominent representatives of these so-called extracellular vesicles (EVs) are nanosized exosomes (70-150 nm), which are derivatives of the endosomal system, and microvesicles (100-1000 nm), which are produced by outward budding of the plasma membrane. Nanosized EVs are released by almost all cell types and mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical, academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST) program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine. © 2016 American Chemical Society.

Indexed keywords

Engineering controlled terms:Cell membranesControlled drug deliveryInternational cooperationMedical nanotechnologyPhospholipidsProgram diagnosticsTargeted drug delivery
Engineering uncontrolled termsIntercellular communicationsMembrane microdomainsPathophysiologicalPhospholipid membranePhysical functionRecent researchesScience and TechnologyTherapeutic agents
Engineering main heading:Diagnosis
EMTREE medical terms:animalcell communicationclinical trial (topic)drug delivery systemexosomehumanmembrane microparticlenanomedicinephysiologytheranostic nanomedicine
MeSH:AnimalsCell CommunicationCell-Derived MicroparticlesClinical Trials as TopicDrug Delivery SystemsExosomesExtracellular VesiclesHumansNanomedicineTheranostic Nanomedicine

Funding details

Funding sponsor Funding number Acronym
European Cooperation in Science and TechnologyBM1202
  • 1

    The authors acknowledge the european COST action for supporting the European Network on Microvesicles and Exosomes in Health and Disease (ME-HaD, BM1202, www. cost.eu/COST-Actions/BMBS/Actions/BM1202) who funded parts of the publication of this work.

  • ISSN: 19360851
  • Source Type: Journal
  • Original language: English
  • DOI: 10.1021/acsnano.5b08015
  • PubMed ID: 26978483
  • Document Type: Review
  • Publisher: American Chemical Society

  Fais, S.; Anti-Tumor Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS), Rome, Italy;
© Copyright 2018 Elsevier B.V., All rights reserved.

Cited by 146 documents

Patel, G.K. , Khan, M.A. , Zubair, H.
Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications
(2019) Scientific Reports
Liu, J. , Ye, Z. , Xiang, M.
Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance
(2019) Biomaterials
Kao, C.-Y. , Papoutsakis, E.T.
Extracellular vesicles: exosomes, microparticles, their parts, and their targets to enable their biomanufacturing and clinical applications
(2019) Current Opinion in Biotechnology
View details of all 146 citations
{"topic":{"name":"Exosomes; Cells; Recipient cells","id":489,"uri":"Topic/489","prominencePercentile":99.9833,"prominencePercentileString":"99.983","overallScholarlyOutput":0},"dig":"a55542e587f01d1934bc33d5ed74b5a379f3bfb1949a5e862477b90a58cc8506"}

SciVal Topic Prominence

Topic:
Prominence percentile: